tbuckley/cabot-search huggingface dataset:
Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)
Authors: Anthony S. Stein, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Max S. Topp, Janet L. Franklin, Ze Cong, Xinke Zhang, Yan Li, Andre Schuh
Journal: Blood (2018)
A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
Authors: Chris Ka Pun Mok, Chunke Chen, Karen Yiu, Tat-On Chan, Kiu Cheung Lai, Kwun Cheung Ling, Yuanxin Sun, David S. Hui, Samuel M. S. Cheng, Malik Peiris
Journal: American Journal of Respiratory and Critical Care Medicine (2022)
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1956)

COMMITTEE ON MATERNAL WELFAREUterine Atony and Post-Partum HemorrhageA thirty-three-year-old gravida 3, para 2, entered the hospital in active labor twelve days after the estimated date of confinement. The blood pressure on admission was 138 systolic, 90 diastolic. Two hours later, under light open-drop ether anesthesia, a normal infant weighing 3.2 kg. (7 pounds, 1 ounce) was delivered by outlet forceps and mediolateral episiotomy. Ergotrate was given intravenously with delivery of the infant, and was repeated five minutes later (at 6:30 a.m.) with delivery of the intact placenta. On completion of the third stage, the patient was bleeding more . . .
Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence
Authors: David F. Fiorentino, Christopher A. Mecoli, Matthew C. Rosen, Lorinda S. Chung, Lisa Christopher-Stine, Antony Rosen, Livia Casciola-Rosen
Journal: Journal of Clinical Investigation (2022)

BACKGROUNDThe temporal clustering of a cancer diagnosis with dermatomyositis (DM) onset is strikingly associated with autoantibodies against transcriptional intermediary factor 1-γ (TIF1-γ). Nevertheless, many patients with anti-TIF1-γ antibodies never develop cancer. We investigated whether additional autoantibodies are found in anti-TIF1-γ-positive patients without cancer.METHODSUsing a proteomic approach, we defined 10 previously undescribed autoantibody specificities in 5 index anti-TIF1-γ-positive DM patients without cancer. These were subsequently examined in discovery (n = 110) and validation (n = 142) cohorts of DM patients with anti-TIF1-γ autoantibodies.RESULTSWe identified 10 potentially novel autoantibodies in anti-TIF1-γ-positive DM patients, 6 with frequencies ranging from 3% to 32% in 2 independent DM cohorts. Autoantibodies recognizing cell division cycle and apoptosis regulator protein 1 (CCAR1) were the most frequent, and were significantly negatively associated with contemporaneous cancer (discovery cohort OR 0.27 [95% CI 0.7-1.00], P = 0.050; validation cohort OR 0.13 [95% CI 0.03-0.59], P = 0.008). When cancer did emerge, it occurred significantly later in anti-CCAR1-positive compared with anti-CCAR1-negative patients (median time from DM onset 4.3 vs. 0.85 years, respectively; P = 0.006). Cancers that emerged were more likely to be localized (89% of anti-CCAR1-positive cancers presenting at stage 0 or 1 compared with 42% of patients without anti-CCAR1 antibodies, P = 0.02). As the number of additional autoantibody specificities increased in anti-TIF1-γ-positive DM patients, the frequency of cancer decreased (P < 0.001).CONCLUSIONAs the diversity of immune responses in anti-TIF1-γ DM patients increases, the likelihood of cancer emerging decreases. Our findings have important relevance for cancer risk stratification in DM patients and for understanding natural immune regulation of cancer in humans.TRIAL REGISTRATIONNot applicable.FUNDING SOURCESThe NIH, the Donald B. and Dorothy L. Stabler Foundation, and the Huayi and Siuling Zhang Discovery Fund.
Alternate Two-Dose Hepatitis B Vaccination Schedule for Adolescents Aged 11-15 Years
Authors: N Kanarek, D Sockwell, H Jia, S Reese, B Bender, G Potts, B Davis, M Leff, M Adams, I Bullo, L Martin, F Reyes-Salvail, J Aydelotte, B Steiner, L Stem- Nock, J Igbokwe, C Hunt, T Sparks, B Bates, D Maines, A Weinstein, Maryland Brooks, H Mcgee, N Salem, D Johnson, T Murayi, P Feigley, L Andelt, E Dejan, Larry Powers, New Hampshire, G Boe- Selager, C Baker, New York
Journal: JAMA (2000)
Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization
Authors: Timm Weber, Julian Potthoff, Sven Bizu, Maurice Labuhn, Leona Dold, Till Schoofs, Marcel Horning, Meryem S. Ercanoglu, Christoph Kreer, Lutz Gieselmann, Kanika Vanshylla, Bettina Langhans, Hanna Janicki, Luisa J. Ströh, Elena Knops, Dirk Nierhoff, Ulrich Spengler, Rolf Kaiser, Pamela J. Bjorkman, Thomas Krey, Dorothea Bankwitz, Nico Pfeifer, Thomas Pietschmann, Andrew I. Flyak, Florian Klein
Journal: Immunity (2022)
Abstract 17073: Intraprocedural Use of Dopamine During Ventricular Tachycardia (VT) Ablation is Associated With Greater Number of VTs Induced and Increased Need for Cardioversions
Authors: Jeffrey D Graham, Michael Rosenberg, Amneet Sandhu, Alexis Tumolo, Wendy Tzou, William Sauer, Ryan Borne, Duy Nguyen
Journal: Circulation (2018)

Introduction: Hemodynamic drugs are frequently used in patients with heart failure, despite arrhythmogenic effects. In certain situations, dopamine has been associated with increased arrhythmias and mortality. There are no known studies reviewing the impact of hemodynamic drugs used during VT ablations on procedural outcomes. Hypothesis: We sought to determine whether intra-procedural use of dopamine, dobutamine, or phenylephrine affected the number of induced VTs, required cardioversions, or the acute success of VT ablations. Methods: We conducted a retrospective review for all VT ablations from 2013-17 at our institution. Patient and procedural details were collected for 149 VT ablations. Results: The cohort was 81% male, and 67% had cardiomyopathy of which 53% were ischemic with a mean EF of 29.1% (CI 26.7- 31.4). Vasoactive drugs were used in 87% of patients undergoing VT ablation: phenylephrine (67%), dopamine (40%), dobutamine (37%). After adjusting for heart failure and procedural time, use of dopamine, but not phenylephrine or dobutamine, was associated with a greater number of induced VTs (p =0.02, Fig. 1a). Adjusting for the same factors, dopamine and dobutamine were significantly associated with increased need for cardioversions (p &lt; 0.01). Dobutamine, but not dopamine or phenylephrine, was associated with lower acute procedural success (OR 0.25, CI 0.08-0.77, P = 0.01). Conclusions: Different vasoactive drugs may have differential effects on VT ablation outcomes. The focus of VT ablation is usually on VT mechanism and substrate, but attention to other factors, such as vasoactive drugs, may be warranted to determine their effect on procedural outcomes.
Thomas Cadwalader (1708-1779)
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bureau of Legal Medicine and Legislation
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 73: Pre- and Post-Translational Regulation of Lysyl Oxidase/β1-Intergrin in Aortic Vascular Smooth Cell of Hypertension
Authors: Ben Ma, Ning Zhou, Shaunrick Stoll, Hongyu Qiu
Journal: Circulation Research (2017)

Background: An increase in aortic stiffness is a fundamental component of hypertension . We previous showed that aortic vascular smooth muscle cells (VSMCs) play an causative role in aortic stiffening not only due to the increased intrinsic stiffness in VSMC itself but also due to its interaction with extracellular matrix (ECM). However, the molecular mechanism involved is unclear. Here, we test the hypothesis that the aortic VSMCs mediates pre- and post-translational regulation of Lysyl Oxidase (Lox)/β1intergrain pathway which may be one of the mechanisms of VSMCs-ECM remodeling in hypertension. Methods and Results: 4 months old male spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats were studied. Aortic pressure and stiffness were measured with an invasive catheter and Doppler imaging echocardiography, respectively. Compared to WKY, SHR showed a significant higher aortic pressure (mean arterial pressure (MAP) 138.7±11.8 vs 102.7±7 mmHg, ( p &lt;0.01) and a greater aorta stiffness reflected by 2.5-fold higher arterial stiffness index (ASI) in SHR vs WKY ( p &lt;0.01). VSMCs were isolated from thoracic aorta, then cultured and measured at passages 2 to 4. Real time PCR and western blot were used to detect the gene and protein expression. Compared to WKY, VSMCs from SHR showed a significant increase in mRNA Lox, a copper-dependent amine oxidase mediating the crosslinking of collagens and elastin (2.7 folds vs WKY, p &lt;0.01). The abundance of LOX protein was significant increased not only at pro-enzyme lox level, but also at the regulatory pro-peptide lox and matured active enzyme Lox in SHR VSMCs by 3.5 folds and 1.4 folds respectively ( p &lt;0.01), indicating an increased post-translational regulation of LOX in SHR VSMCs. In addition, the glycosylated β1 integrin, a transmembrane receptor that facilitate cell-ECM adhesion, was found to be significant increase in SHR VSMCs vs WKY. Conclusion: The regulation of pre- and post-translational regulation of Lox/β1intergrain pathway in aortic VSMCs presents a novel mechanism of cell-ECM interaction, which may contribute to the increased aortic stiffness in SHR.
American University of Beirut
Authors: W. M. Bickers
Journal: JAMA (1967)

This is the centennial year for the American University of Beirut in Lebanon. Alumni from the far-flung corners of the earth will converge upon this subtropical campus to celebrate the 100th birthday of a very unique institution. Doctors and lawyers, merchants and teachers, leaders of government, and sons of royalty will come from the sandy wastes of Arabia, from the hospitals and universities of the Sudan and Egypt, from Damascus and Jerusalem. Teachers and scholars from Europe and America will join the alumni of the Arab world to pay homage to their alma mater. Graduates from this university who carried the ideals and philosophy of its founder to their native lands will return this year to the source of their inspiration. In an atmosphere of freedom, the university, like Lebanon, is truly a meeting place for East and West. The campus and classrooms provide a living laboratory for students of
Epigenetic Regulation of <i>F2RL3</i> Associates With Myocardial Infarction and Platelet Function
Authors: Laura J. Corbin, Stephen J. White, Amy E. Taylor, Christopher M. Williams, Kurt Taylor, Marion T. van den Bosch, Jack E. Teasdale, Matthew Jones, Mark Bond, Matthew T. Harper, Louise Falk, Alix Groom, Georgina G.J. Hazell, Lavinia Paternoster, Marcus R. Munafò, Børge G. Nordestgaard, Anne Tybjærg-Hansen, Stig E. Bojesen, Caroline Relton, Josine L. Min, George Davey Smith, Andrew D. Mumford, Alastair W. Poole, Nicholas J. Timpson
Journal: Circulation Research (2022)

DNA hypomethylation at the
Measurement and Evaluation of Radioactivity in Man
Journal: JNCI Journal of the National Cancer Institute (1962)

Measurement and Evaluation of Radioactivity in Man JNCI: Journal of the National Cancer Institute, Volume 29, Issue 6, December 1962, Pages 1198–1199, https://doi.org/10.1093/jnci/29.6.1198-a Published: 01 December 1962
Endomyocardial cytokine gene expression and LV-massindex in patients with idiopathic dilated cardiomyopathy Marc Vanderheyden, Georg Baumgarten, Douglas Mann, Walter J. Paulus. Cardiovascular Center, OLV ziekenhuis, Aalst, Belgium, Baylor College of Medicine, Houston, TX
Journal: Journal of the American College of Cardiology (2001)
Aortic distensibility is independently correlated with exercise tolerance in patients with dilated cardiomyopathy Stefano Bonapace, Mariantonietta Cicoira, Lorenzo Franceschini, Luisa Zanolla, Giorgio Golia, Piero Zardini, Andrea Rossi. Universita' di Verona, Verona, Italy
Journal: Journal of the American College of Cardiology (2001)
Therapeutic Inertia and Racial Differences in Blood Pressure Control—Time to Get Moving
Authors: Matthew B. Rivara, Nisha Bansal, Bessie Young
Journal: JAMA Network Open (2022)

Alexander R. Zheutlin, MD, MS; Favel L. Mondesir, PhD, MSPH; Catherine G. Derington, PharmD, MS; Jordan B. King, PharmD, MS; Chong Zhang, MS; Jordana B. Cohen, MD, MSCE; Dan R. Berlowitz, MD, MPH; D. Edmund Anstey, MD, MPH; William C. Cushman, MD; Tom H. Greene, PhD; Olugbenga Ogedegbe, MD, MPH; Adam P. Bress, PharmD, MS
E.O.R.T.C. Symposium on Treatment of Advanced Gastrointestinal Cancer
Journal: JNCI Journal of the National Cancer Institute (1982)

E.O.R.T.C. Symposium on Treatment of Advanced Gastrointestinal Cancer JNCI: Journal of the National Cancer Institute, Volume 69, Issue 5, November 1982, Page 1206, https://doi.org/10.1093/jnci/69.5.1206-a Published: 01 November 1982
Genetic diversity and persistent transmission of norovirus in Shenzhen, China, 2016–2018
Authors: Xiaofeng Hu, Yaqing He, Yuan Jin, Hui Ma, Baichuan Xu, Chunyan Shao, Kangkang Liu, Lianqun Jin, Chuanfu Zhang, Shengnan Liang, Mingda Hu, Hailong Zhang, Sai Tian, Hong Yang, Yang Xiao, Hongbin Song, Hongguang Ren, Shaofu Qiu
Journal: Journal of Infection (2022)
TCT-89 Timing, Predictive Factors and Prognostic Value of Cerebrovascular Events in a Large Cohort of Patients Undergoing Transcatheter Aortic Valve Implantation
Authors: Luis Nombela-Franco, John Webb, Peter De Jaegere, Stefan Toggweiler, Jan Nuis Rutger, Antonio Dager, Ignacio Amat-Santos, Anson Cheung, Jian Ye, Robert M.A. Van Der Boon, Nicolas Van Mieghem, Luis Benitez, Ronald Binder, Sergio Perez, Javier Lopez, Alberto San Roman, Daniel Doyle, Robert De Larochelliere, Jonathon Leipsic, Eric Dumont, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2012)
Facts and Hopes in Multiple Myeloma Immunotherapy
Authors: Adam S. Sperling, Kenneth C. Anderson
Journal: Clinical Cancer Research (2021)

Abstract Among the hallmarks of cancer is the ability of neoplastic cells to evade and suppress immune surveillance to allow their growth and evolution. Nowhere is this as apparent as in multiple myeloma, a cancer of antibody-producing plasma cells, where a complex interplay between neoplastic cells and the immune microenvironment is required for the development and progression of disease. Decades of research has led to the discovery of a number of therapeutic agents, from cytotoxic drugs to genetically engineered cells that mediate their antimyeloma effects at least partially through altering these immune interactions. In this review, we discuss the history of immunotherapy and current practices in multiple myeloma, as well as the advances that promise to one day offer a cure for this deadly disease.
Abstract P318: Neighborhood Environment Characteristics and Control of Cardiovascular Disease Risk Factors in a Primary Care Patient Sample
Authors: M. Maya McDoom-Echebiri, Yea-Jen Hsu, Lisa A Cooper, Rachel J Thornton
Journal: Circulation (2018)

Introduction: Hypertension and diabetes control are leading modifiable risk factors for cardiovascular disease (CVD) risk. Contemporary epidemiological research suggests that individual and health system characteristics are associated with control. Yet, there is little evidence examining how the neighborhood environment influences hypertension or diabetes control among patients engaged in primary care. Methods: We analyzed data of adult patients (n = 5,711) with hypertension or diabetes who received primary care at 1 of 3 clinics of a statewide health care organization in Baltimore, MD and lived within the Baltimore city limits. The neighborhood environment exposures were tertiles of neighborhood socioeconomic status (SES), crime, and healthy food availability index (HFAI) assessed at the census tract level. Separate multivariate logistic regression models were constructed to estimate the odds ratio (OR) for each of these neighborhood environment characteristics and hypertension and diabetes control, adjusting for patient demographics, and health behaviors; and for physician demographic characteristics. Results: The overall mean age was 57.8 ± 14.3 years, 67.2% were female, and 89.6% were Black. There were 5,325 patients with hypertension and 2,094 patients with diabetes (not mutually exclusive). In bivariate analyses, high neighborhood SES (p= 0.030) and low crime (p= 0.006) were associated with hypertension control, and none of the neighborhood exposures were associated with diabetes control. In fully adjusted analyses, being Black was significantly associated with decreased odds of hypertension control in all models (OR range: 0.63 – 0.65), independent of neighborhood exposures. Among those with hypertension, living in a low or moderate SES neighborhood or a high crime neighborhood was associated with lower odds of hypertension control; however, these associations were attenuated in adjusted models. None of the neighborhood exposures were significantly associated with odds of diabetes control in models that adjusted for patient characteristics. Yet, compared to high SES neighborhoods, living in a low or moderate SES neighborhood (OR=0.74, 95% CI: 0.57 - 0.97 and OR=0.75, 95% CI: 0.57 - 0.98, respectively) was associated with reduced diabetes control after adjusting for both patient and physician characteristics. Conclusion: Exposure to neighborhood disadvantage may contribute to poor diabetes and hypertension control among patients in primary care, independent of patient and physician characteristics. Patient-centered risk assessments including measures of social need and preventive interventions adapted to neighborhood environments could be useful for optimizing hypertension and diabetes control in clinical settings.
Outcome of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).
Authors: Lakhan Kashyap, Vijay Maruti Patil, Sachin Dhumal, Vanita Noronha, Amit Joshi, Nandini Menon, Kumar Prabhash
Journal: Journal of Clinical Oncology (2021)

e18034 Background: NACT is often used in technically unresectable oral cavity SCC to improve resection rate. NACT regimen based on combination of maximum tolerated doses (MTD) and metronomic chemotherapy will debulk the tumor and subsequently inhibit angiogenesis which may overcome drug resistance of MTD schedule. We assessed outcome and tolerance of this combination as NACT in patients with technically unresectable oral cavity SCC. Methods: This is retrospective analysis of prospectively maintained data. Fourteen patients having technically unresectable oral cavity SCC received NACT with paclitaxel (175mg/m2) plus carboplatin (AUC5) every 3 weekly (MTD schedule) and OMCT (methotrexate 9mg/m2 once a week, celecoxib 200mg twice daily and erlotinib 150mg once daily). Patient were assessed clinically and radiologically after minimum of two cycles for surgery. Kaplan-Meier method was used for survival analysis. We report resectability, survival and tolerance of this regimen. Results: Median age of the patients was 38 years, and twelve patients (85%) were male. Twelve (85%) and two (15%) patients had buccal mucosa and oral tongue primary, respectively. AJCC 2017 stage IVA and IVB disease was present in twelve (85%) and two (15%) patients, respectively. Reason for technical unresectabilty was skin edema above zygoma in five (36%), high infratemporal fossa involvement in five (36%), nodal encasement of major vessels in two (14%) and posterior extent of oral tongue tumor into oropharynx in two (14%) patients. Median number of NACT administered were three. Tumor of nine patients (65%; 95% CI = 39%-89%) were deemed resectable after NACT. Eight patients underwent surgery and tumor of one patient showed pathologic complete response. Median follow up was 14.6 months (95% CI = 14.1 - 15 months). Median progression free survival was 11.4 months (95% CI = 7.9 – 15 months). Median overall survival (OS) was not reached while OS at 15 months was 63.5% (95% CI = 37.8% - 89.2%). Common grade 3/4 toxicities (CTCAE 5.0) were neutropenia in eight (57%), thrombocytopenia in three (21%), febrile neutropenia, hypokalemia and diarrhoea in two patients (14%) each. Two patients required in-patient supportive care for adverse events. Conclusions: Paclitaxel and carboplatin along with OMCT is well tolerated and less resource intensive regimen which leads to favorable resection rate and survival in patients with technically unresectable oral cavity SCC.